Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
about
Computational Identification of Novel Stage-Specific Biomarkers in Colorectal Cancer ProgressionIdentification of capsazepine as a novel inhibitor of system xc- and cancer-induced bone pain.Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain.Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism.Metabotropic glutamate receptors in cancer.1,25-Dihydroxyvitamin D induces the glutamate transporter SLC1A1 and alters glutamate handling in non-transformed mammary cells.Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas.Molecular Basis for Modulation of Metabotropic Glutamate Receptors and Their Drug Actions by Extracellular Ca2Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells.Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA-MB-231 cellsMetabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer
P2860
Q28552533-E3D95C38-92E5-41BB-B1FF-7345B9FAF2AAQ33596824-82B79CA2-DCC8-45C5-8D32-0A18FD382550Q34525011-C8B79EE7-17AC-4E49-BBB9-2075647A9B16Q35070083-1E01A391-D290-4746-B857-CDD50C601D73Q37594451-C91E7A7A-A22E-4DC0-9666-99B0CEA079ECQ38741884-38D92F25-4B90-46C0-9717-45744F5872D7Q38794334-F2DA15D6-E848-457F-A5CE-5313855EB3A4Q38971337-B8B15456-9B73-4547-B4F5-6D5849201716Q39196723-896F25B3-75E5-4D3D-A840-A00E596CB98AQ41280249-5547BA18-8E8D-40D8-B83D-23E6AA413E73Q46311036-EAFE8300-A9F5-4AFA-8E80-F94830D191D0Q47164952-F08904FF-D8D4-4893-B729-622D0CDF68EBQ47986792-767AEB87-E870-4F2D-AB92-C7485F14D8C0Q57787055-946F3C59-B935-4DCF-8183-4D062B7EAA87Q58098917-78B504BB-B443-4346-9943-077EC883F386
P2860
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabotropic glutamate recepto ...... triple negative breast cancer.
@en
Metabotropic glutamate recepto ...... triple negative breast cancer.
@nl
type
label
Metabotropic glutamate recepto ...... triple negative breast cancer.
@en
Metabotropic glutamate recepto ...... triple negative breast cancer.
@nl
prefLabel
Metabotropic glutamate recepto ...... triple negative breast cancer.
@en
Metabotropic glutamate recepto ...... triple negative breast cancer.
@nl
P2093
P2860
P1433
P1476
Metabotropic glutamate recepto ...... triple negative breast cancer.
@en
P2093
Bonnie F Sloane
Cecilia L Speyer
David H Gorski
Fred R Miller
Hyunjin J Kim
James S Goydos
Keila E Torres Torres
Kingsley O Osuala
Malathi Banda
Nicola J Barnard
P2860
P304
P356
10.1371/JOURNAL.PONE.0081126
P407
P577
2014-01-03T00:00:00Z